Using Quantitative Systems Pharmacology Modeling to Understand the Pathophysiology of Idiopathic Pulmonary Fibrosis

Using Quantitative Systems Pharmacology Modeling to Understand the Pathophysiology of Idiopathic Pulmonary Fibrosis

Authors: Siler SQ, Longo DM, Woodhead JL, Battista C, Kenz Z, Tallapaka SB, Liu G, Generaux GT, Ermakov S, Shoda LKM
Conference: American Thoracic Society (ATS) International Congress
Keywords: epithelial cell health, fibroblasts, IPFsym, nintedanib, pulmonary playlist, quantitative systems pharmacology (QSP), SimPops
Software: IPFsym®
Division: Quantitative Systems Pharmacology (QSP)

Patients with idiopathic pulmonary fibrosis (IPF) have a poor survival prognosis and limited treatment options.

Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia

Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia

Authors: Lee JB, Zang X, Zgair A, Ooi TQ, Foley DW, Voronin G, Kagan L, Soukarieh F, Gao R, Shao H, Soh WT, Kim TH, Kim MG, Yun HY, Wilson AJ, Fischer PM, Gershkovich P
Publication: Eur J Pharm Biopharm
Keywords: colonic absorption, extended release, food effect, gastroplus, mechanistic absorption, pbbm, PBPK modeling, physiologically based biopharmaceutics modeling
Software: GastroPlus®

For treatment of chronic cancers, the oral administration route is preferred as it provides numerous advantages over other delivery routes.

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists

Authors: Henrich A, Claussen CH, Dingemanse J, Krause A
Publication: CPT Pharmacometrics Syst Pharmacol
Keywords: P2Y12 receptor antagonists, pharmacodynamics, pharmacokinetics (PK)

Selatogrel is a potent and reversible P2Y12 receptor antagonist developed for subcutaneous self‐administration by patients with suspected acute myocardial infarction.

Human-on-a-Chip combined with PBPK modeling for in vitro/in vivo PK/PD extrapolation

Human-on-a-Chip combined with PBPK modeling for in vitro/in vivo PK/PD extrapolation

Authors: Hickman J, Lukacova V
Keywords: drug-drug interactions (DDIs), gastroplus, Human-on-a-Chip (HoaC) systems, in vitro, PK prediction
Software: GastroPlus®
Division: PBPK

Human-on-a-Chip (HoaC) systems are becoming valuable tools to study, understand disease physiology, and expand the prediction of pharmacodynamic effects before first-in-human studies. They can also be used to evaluate the toxic effects of compounds in non-pharma industries where these effects cannot be examined in vivo.

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Authors: Thomas M, Brand S, De Rycker M, Zuccotto F, Lukac I, Dodd PG, Ko EJ, Manthri S, McGonagle K, Osuna-Cabello M, Riley J, Pont C, Simeons F, Stojanovski L, Thomas J, Thompson S, Viayna E, Fiandor JM, Martin J, Wyatt PG, Miles TJ, Read KD, Marco M, Gilbert IH
Publication: J Med Chem
Keywords: admet predictor, aqueous solubility, drug design, drug discovery, gastroplus, machine learning
Software: GastroPlus®

There is an urgent need for new treatments for visceral leishmaniasis (VL), a parasitic infection which impacts heavily large areas of East Africa, Asia, and South America